Ewing sarcoma breakpoint region 1–Friend leukemia integration 1 transcription factor–DNA complex (EWS-FLI1–DNA complex)

The EWS-FLI1 transcription factor–DNA complex is the primary oncogenic driver of Ewing sarcoma, a bone and soft tissue malignancy primarily affecting children and young adults (Riggi et al., 2014, Cancer Discovery). This complex is formed by the chromosomal translocation t(11;22)(q24;q12), which fuses the amino-terminal transactivation domain of EWSR1 with the carboxyl-terminal DNA-binding domain of the FLI1 protein (UniProt P15502/Q01543). The resulting chimeric protein acts as an aberrant transcription factor that specifically targets and binds to GGAA-rich microsatellites, which it converts into neo-enhancers to dysregulate hundreds of genes involved in cell cycle progression and survival (Gangwal et al., 2008, Genes & Cancer). Because this fusion protein is unique to tumor cells and absent in healthy tissue, it represents an ideal therapeutic target. Pharmacological strategies include small molecules like YK-4-279, which disrupts the interaction between EWS-FLI1 and its essential cofactor RNA Helicase A, and DNA-binding agents like Mithramycin A that displace the complex from its genomic targets (Erkizan et al., 2009, Nature Medicine; Grohar et al., 2011, JNCI). Despite its high specificity, the complex is historically considered "undruggable" due to its lack of a traditional enzymatic pocket and its reliance on disordered protein-protein interactions.

Other names

EWSR1-FLI1 fusion proteinEWS-FLI1/GGAA-microsatellite complexEWS-FLI1 transcription factort(11;22)(q24;q12) fusion product

Disruption of protein-protein interactions between the fusion protein and transcriptional co-regulators (e.g., RNA Helicase A), or direct interference with DNA binding at GGAA-rich microsatellite sites to inhibit oncogenic gene expression.